Israeli company reveals nasal spray of psychedelic mushrooms
Al-Monitor, 09 May, 2022
Madrigal Mental Care says the spray treats post-traumatic stress disorder, anxiety and other mental challenges. Some experts believe magic mushrooms have health benefits, though they come with risks.
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
Globe News Wire, 03 May, 2022
Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans.
Trending Clinical Topic: Psychedelics
MedScape, 22 April, 2022
A new study examined changes in specific neurotransmitter systems and brain regions that may be responsible for various experiences associated with a psychedelic “trip”.
Australian researchers trialling magic mushroom active ingredient as antidepressant
9 News, 27 April, 2022
Sydney researchers are testing psilocybin as an alternative to antidepressants.
GoDaddy Billionaire Bob Parsons Believes Psychedelics Can Heal Trauma—And He’s Putting His Money (And Brain) On The Line
Forbes, 17 April, 2022
The Marine infantryman still suffers from PTSD from his tour in Vietnam but credits LSD and MDMA with helping him “come home.” Now he’s on a mission to help other veterans.
‘Magic mushrooms’ for PTSD therapy? Vets help sway conservatives
LA Times, 16 April, 2022
Matthew Butler spent 27 years in the Army, but it took a day in jail to convince him that his post-traumatic stress disorder was out of control.
Mushrooms’ magic compound latest hope to relieve depression
The Australian, 12 April, 2022
Early tests show lasting effects of brain ‘rewiring’ following controlled ‘trips’
Psychedelic frees up depressed brain, study shows
BBC News, 12 April, 2022
Psilocybin appears to free up the brains of people with severe depression in a way that other antidepressants do not, a study has found.
What the science says about microdosing
Australian Financial Review, 08 April, 2022
Scientists have insight into what happens when someone takes enough psychedelics to experience hallucinogenic effects. But little research has been conducted on the effects of small doses.
6 terminally ill cancer patients in Canada received doses of the psychoactive substance found in 'magic' mushrooms after authorities eased rules
Business Insider, 07 April, 2022
Six terminally ill cancer patients in Canada received the country’s first legally produced psilocybin under new rules about access to the substance.
Psychedelics may ease cancer patients’ depression, anxiety
Washington Post, 02 April, 2022
Evidence indicates that psychedelics could reduce the end-of-life anxiety that many cancer patients experience.
The Next Big Addiction Treatment
New York Times, 31 March, 2022
Psilocybin combined with therapy is emerging as one of the most effective psychedelic therapies.
Why microdosing is gaining momentum in Australia
Australian Financial Review, 24 March, 2022
Microdosing psychedelic drugs has been a trend in Silicon Valley that’s taking off here. But does a micro trip help you make better decisions at work?
Read the full PDF article here.
LSD, a future anti-anxiety pill?
McGill University Health Centre, 18 March, 2022
A study conducted by Gabriella Gobbi, MD, Professor and Head of the Neurobiological Psychiatry Unit in the Department of Psychiatry, and her team demonstrates for the first time that regular administration of low doses of LSD (lysergic acid diethylamide) reduces anxiety symptoms through neurobiological mechanisms that are similar to those of selective serotonin reuptake inhibitors (SSRIs).
Johns Hopkins, Yale, and NYU are teaming up to tackle a key bottleneck that will arise as psychedelics come to market
Business Insider, 11 March, 2022
As psychedelics treatments move closer to regulatory approval, there’s an issue looming in the industry: the lack of trained professionals who can handle such powerful compounds.
MDMA-assisted psychotherapy for PTSD could save the health care system millions of dollars, study suggests
PsyPost, 11 March, 2022
New research provides evidence that MDMA-assisted psychotherapy can improve and extend lives of patients with chronic and severe post-traumatic stress disorder while also reducing healthcare costs.
Oklahoma House Passes Psilocybin Decriminalization Bill
Psychedelics Spotlight, 09 March, 2022
On Monday, the state’s Republican-controlled House of Representatives voted overwhelmingly, 62-30, to pass House Bill 3414, introduced by Rep. Daniel Pae (R).
4 Signs the Psychedelics Movement Is Unstoppable
Psychedelics Spotlight, 28 February, 2022
Dr. Nora Volkow, the Director of the National Institute on Drug Abuse, said earlier this year that the psychedelics “train has left the station,” and here are four big reasons to agree wholeheartedly.
Psilocybin Treatment for Major Depression Effective for up to a Year for Most Patients
Neuroscience News, 15 February, 2022
The antidepressant effect of psilocybin-assisted therapy, in combination with psychotherapy, appears to provide up to a year of symptom relief for some patients with major depressive disorder.
Two doses of psilocybin may ease depression symptoms for up to 12 months
News Medical, 15 February, 2022
Previous studies by Johns Hopkins Medicine researchers showed that psychedelic treatment with psilocybin relieved major depressive disorder symptoms in adults for up to a month. Now, in a follow-up study of those participants, the researchers report that the substantial antidepressant effects of psilocybin-assisted therapy, given with supportive psychotherapy, may last at least a year for some patients.
Plant-based Medicines
Colorado General Assembly, 10 February, 2022
Concerning establishing a policy review panel to study plant-based medicines to support mental health.
Psychedelics and the Future of Psychiatry
Psychiatric Times, 09 February, 2022
Over the past several years, we have witnessed a psychedelic renaissance, and a growing body of evidence suggests that several psychedelic compounds hold strong therapeutic potential for a wide array of mental health conditions.
Psychedelic therapy shows great promise. More states should legalise it
The Economist, 29 January, 2022
Oregon’s trailblazing sets a fine example.
Sensible policy on psychedelic drugs is growing more common
The Economist, 29 January, 2022
They show tremendous potential in treating certain mental health disorders.
Read the full PDF article here.
Or listen to the topic being discussed on The Economist Podcast.
The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of
VICE, 25 January, 2022
Scientists are designing new psychedelic-inspired drugs that don’t yet exist, which might have effects no one can yet describe.
Ketamine for the treatment of alcoholism
Blossom Analysis, 24 January, 2022
Psychedelics are poised to be both viable and effective treatment options for many people living with mental disorders whom conventional treatments have failed. One of these disorders is substance use disorder (SUD), commonly known as addiction.
Psychedelics Offer New Route to Recovery from Eating Disorders
Neo.Life, 01 February, 2022
Psilocybin, MDMA, and ketamine can lead to a new sense of self and a release from rigid rules for people with anorexia, bulimia, and binge-eating disorder.
How 2021 became the year of psychedelics – and why 2022 is set to be even bigger
Canex, 20 January, 2022
It’s no secret that psychedelics are on the comeback trail, with a record number of trials and total investment in the hundreds of millions of dollars in 2021 alone.
Health Canada’s New SAP Rules: A Q&A With Numinus’ Payton Nyquvest
Psychedelic Stock Watch, 10 January, 2022
In 2020, Health Canada began tentative steps to open up legal access to psychedelics-based therapies via “exemptions” granted through its Special Access Program (SAP).
Details from the program can be found here.
$14.8 million for innovative mental health clinical trials
Health.gov.au, 07 January, 2022
Seven clinical trials testing the use of potential breakthrough combination therapies to treat debilitating mental illnesses will receive a total of almost $15 million from the Australian Government’s Medical Research Future Fund (MRFF).
Therapists hail 'legalization' of medicinal psychedelic drugs
Calgary Herald, 07 January, 2022
Local therapists say Ottawa’s move allowing physicians to prescribe psychedelics is a “seismic shift” towards legalizing their medicinal use.
Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA
Benzinga, 05 January, 2022
In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies with restricted drugs, including MDMA and psilocybin.
Depression and Grief Wrecked a Man's Life—Until He Took Magic Mushroom Ingredient
Newsweek, 26 December, 2021
Five years after taking part in a clinical trial, Kirk Rutter, spoke to Newsweek about his experiences of the trial and its impact on his mental health.
New center to study psychedelics pops up at University of Texas at Austin
My Sanantonio, 20 December, 2021
The Dell Medical School at the University of Texas at Austin is launching the Center for Psychedelic Research and Therapy, the first-of-its-kind center dedicated to the research of drugs such as psilocybin mushrooms, ayahuasca, MDMA, and ibogaine.
New Filing Challenges Compass Pathways’ Infamous Patent on Synthetic Psilocybin
VICE, 16 December, 2021
The non-profit Freedom to Operate used research from chemists and crystallographers to argue in a legal filing that Compass’ form of synthetic psilocybin is not a new invention.
Exclusive: Three Canadians with mental health conditions receive legal access to psilocybin mushrooms
The Growth Op, 13 December, 2021
Three Canadians struggling with mental health conditions have received exemptions to the Controlled Drugs and Substances Act from the federal Minister of Health Jean-Yves Duclos.
'This isn’t the 60s again’: psychedelics business takes off amid culture clash
The Guardian, 12 December, 2021
Experts fear if psychedelics fall exclusively into the hands of big pharma the industry will follow the same path as legal marijuana, making the rich richer.
Psychedelics for mental illness
ABC All in the Mind, 12 December, 2021
Major trials are bringing us a step closer to seeing psychedelic substances used in therapy practice for PTSD, anxiety and depression. On this episode of All in the Mind, we take a look at where the research is currently at with our Ambassadors Dr Rick Doblin and Professor David Nutt.
Psychedelics can change humanity for the better. It’s time to unlock their power
The Guardian, 26 November, 2021
Founder and Executive Director at MAPS and an Ambassador for Mind Medicine Australia, Dr Rick Doblin (USA) is at the heart of the psychedelic movement. In this article he shares some of his findings and progress.
Doctor takes bid to treat patient with MDMA to court, in first case of its kind in Australia
ABC News, 12 November, 2021
There’s growing interest in the use of psychedelic medicine in the treatment of complex mental health disorders like depression and PTSD.
New research brings psychedelic drugs a step closer to medical use
ABC: RN Breakfast with Fran Kelly, 10 November, 2021
There’s growing interest in the use of psychedelic medicine in the treatment of complex mental health disorders like depression and PTSD.
Monash presses go on psychedelics to tackle ‘mental health tsunami’
The Sydney Morning Herald, 10 November, 2021
Monash University has set its sights on capturing a slice of the multibillion dollar psychedelic medicines market, with the launch of a drug development centre for new psychiatric treatments, including those using MDMA and psilocybin.
Major announcement: COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
Globenewswire, 09 November, 2021
Largest randomised, controlled, double-blind psilocybin therapy study ever completed shows rapid and sustained response for patients receiving a single dose of COMP360 psilocybin with psychological support.
Will the magic of psychedelics transform psychiatry?
The Guardian, 07 November, 2021
Imagine a medicine that could help people process disturbing memories, sparking behavioural changes rather than merely burying and suppressing symptoms and trauma.
New research shows how psychedelic medicines can help people with PTSD
Today.com, 05 November, 2021
TODAY’s Savannah Guthrie spoke to two patients whose lives have been changed by the therapy.
World-first trial of psilocybin therapy for anxiety disorders to begin in Australia
Happymag, 01 November, 2021
Incannex Healthcare, in partnership with Monash University, has obtained ethics approval to begin the first-ever clinical trial investigating the effects of psilocybin assisted psychotherapy to treat generalised anxiety disorder (GAD).
Johns Hopkins Receives $4M From NIH To Study Psilocybin As Tool To Quit Smoking
Ganjapreneur, 22 October, 2021
Baltimore’s Johns Hopkins Medicine announced that the National Institutes of Health will provide nearly $4 million to help researchers study how psilocybin can affect tobacco addiction.
DEA Wants Way More Cannabis & Psychedelics for Research In 2022
Ganjapreneur, 18 October, 2021
The DEA has proposed massively increasing the production of research-grade cannabis and psychedelics like LSD, psilocybin, and MDMA next year.
Psychedelic research renaissance: The urgent quest for new mental health medicines
Lens Monash, 15 October, 2021
“There’s been a resurgence in research and interest in psychedelic medicine over the past two decades, and particularly so over the past five years,” says Dr Liknaitzky.
Could mushrooms, molly and acid be the new wave of mental health care?
NBC News, 13 October, 2021
Doctors are looking into psychedelics to possibly reduce anxiety and depression. NBC News’ Maya Eaglin reports on the new wave of mental health care.
National anxiety crisis worsens
The Australian, 03 October, 2021
Australians are reporting depression, anxiety and stress at higher rates than the same time last year, with four in five experiencing poor mental health, and children and young people the most seriously affected, as pandemic uncertainty and lockdowns continue to take a toll.
Psychedelic biotech Psylo raises first funds
The Australian, 01 October, 2021
There’s a growing pool of funds being invested in psychedelic research.
Psychedelics might reduce internalized shame and complex trauma symptoms in those with a history of childhood abuse
Psypost.org, 30 September, 2021
The use of psychedelic medicines is associated with lower levels of complex posttraumatic stress symptoms and internalized shame in adults who suffered maltreatment in childhood, according to new research published in the journal Chronic Stress.
Magic Mushrooms May Be the Biggest Advance in Treating Depression Since Prozac
Newsweek, 22 September, 2021
Psilocybin could be the biggest advance since Prozac.
Small pharma successfully completes phase 1 clinical trial of DMT in combination with supportive psychotherapy
Smallpharma.co.uk, 21 September, 2021
Small Pharma’s DMT-assisted therapy (SPL026) demonstrated to be well-tolerated and safe in psychedelic naïve volunteers.
Medicinal cannabis company Little Green Pharma gets green light for psychedelic drug production
ABC News, 10 September, 2021
A WA-based medicinal cannabis company has been given regulatory approval to produce psilocybin, a hallucinogenic substance found in magic mushrooms, to supply for medical research.
The worldview-changing drugs poised to go mainstream
BBC, 07 September, 2021
Our Ambassador Dr Rick Doblin (USA) is featured in this article by the BBC: The worldview-changing drugs poised to go mainstream.
Suicide line records highest number of calls in history
The Australian, 20 August, 2021
Australia’s biggest suicide support line has recorded the most calls for help it has ever received in one day, amid concerns about long-term mental health consequences of Covid-19 restrictions.
Read the article here or the PDF attached.
TGA appoints Independent Expert Panel on MDMA and psilocybin
TGA, 05 August, 2021
The Therapeutic Goods Administration (TGA) Scheduling Delegate (decision maker) has deferred the final decision on applications to down-schedule MDMA and psilocybin from schedule 9 (prohibited drug) to schedule 8 (controlled drug) pending a review into the therapeutic value, risks and benefits to public health outcomes for these substances. The Independent Expert Panel to undertake this review has now been established.
Canadians Overwhelmingly Support Legal Access to Psilocybin-Assisted Therapy, Poll Reveals
Psilocybin Alpha, 04 August, 2021
A new poll, commissioned by the Canadian Psychedelic Association, has highlighted widespread support for legal access to psilocybin-assisted therapy among Canadians.
New Yale Study Shows Psilocybin Spurs Growth of Neural Connections Lost in Depression
Microdose.buzz, 03 August, 2021
A new study conducted by researchers at Yale University showed psilocybin can facilitate the regrowth of neurons lost in depression.
Just One Dose of Magic Mushroom Compound Regrows Lost Brain Connections in Mice
Science Alert, 06 July, 2021
Psilocybin, the active psychedelic compound, has some curious effects on the human brain.
Psychedelic IPOs build momentum as Atai Life Sciences goes public
PitchBook, 18 June, 2021
Making its Wall Street debut, Peter Thiel-backed Atai Life Sciences has become the third biotech company focused on psychedelic treatment for mental health disorders to list on a major US stock exchange.
My team’s research shows magic mushrooms treat depression, but undoing the stigma will be a bigger challenge
iNews, 03 June, 2021
Bringing psychedelic therapy into mainstream treatment will present some major challenges.
Magic mushroom microdosing: Kiwis call for 'life-saving' treatment to be legalised | Newshub Nation
Newshub, 01 June, 2021
Everyday Kiwis with devastating illnesses are turning to small doses of psychedelic medicines to find relief and are calling for a ‘life-saving’ treatment to be made legal for medical purposes.
Ketamine a game changer in treating eating disorders
Toronto Sun, 29 May, 2021
Ketamine, MDMA and psilocybin are proving useful with treatment-resistant mental illnesses, including eating disorders.
Magic mushroom microdosing: Sick Kiwis call for 'life-saving' Class-A drug to be legalised
Newshub, 29 May, 2021
Every day Kiwis with devastating illnesses are turning to small doses of psychedelics to find relief and are calling for what they call a ‘life-saving’ treatment to be made legal for medical purposes.
Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke
Globe News Wire, 27 May, 2021
Algernon recently established a clinical research program for the treatment of stroke focused on DMT.
Could the ‘spirit molecule’ be a treatment option for stroke?
Vancouver Sun, 25 May, 2021
Researchers have spent decades and billions of dollars unsuccessfully searching for novel treatments for stroke. Now a Vancouver-based company is putting a unique hypothesis to the test.
Who’s in Charge of Psilocybin?
Chacruna, 10 May, 2021
From clinicians and investors to Indigenous groups and activists, debate is raging over whether psychedelics are spiritual tools, new psychiatric drugs, medicines for social change, or all of the above.
Psychedelic medicine is about to blow up
Fast Company, 11 May, 2021
New clinical data shows that MDMA-assisted therapy can have a significant impact on PTSD, paving the way for FDA approval and commercialization.
The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.
The New York Times, 09 May, 2021
Psilocybin and MDMA are poised to be the hottest new therapeutics since Prozac. Universities want in, and so does Wall Street. Some worry a push to loosen access could bring unintended consequences.
Legalise 'magic mushrooms' to help cure depression, says London scientist
My London, 06 May, 2021
The director of a pioneering psychedelic research centre on the benefits and limitations of psychedelics for depression.
A Psychedelic Drug Passes a Big Test for PTSD Treatment
The New York Times, 03 May, 2021
A new study shows that MDMA can bring relief when paired with talk therapy to those with severe post-traumatic stress disorder.
MAPS’ Phase 3 Trial of MDMA-Assisted Therapy for PTSD Achieves Successful Results for Patients with Severe, Chronic PTSD
Maps.org, 03 May, 2021
The first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) replicated and expanded on Phase 2 results indicating MDMA-assisted therapy may be an effective and cost-saving treatment for PTSD resulting from any cause.
There Is a Lot of Fungus Among Us
The New York Times, 24 April, 2021
Coffee for immune support. Supplements for inflammation. And psychedelics promising relief from serious ailments. Mushrooms are everywhere, and investors are paying attention.
Massachusetts General Hospital Launches Center to Study Neuroscience of Psychedelics
The Crimson, 23 April, 2021
Massachusetts General Hospital, an affiliate of Harvard Medical School, launched a new center to study the clinical benefits of psychedelics in treating mental illness.